Nine Continents Medical developed implantable tibial nerve stimulator to treat overactive bladder. Credit: Nevit Dilmen.

Danish medical device company Coloplast has acquired implantable tibial nerve stimulation (ITNS) treatment developer Nine Continents Medical for $145m.

The acquisition price includes upfront cash payment and an additional contingent future milestone payment.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Nine Continents Medical, which was established in 2014, developed ITNS as a treatment for overactive bladder (OAB).

OAB is a condition characterised by a variety of symptoms, including the need to urinate more frequently, increased urgency, incontinence or leakage, and a need to urinate at night.

ITNS is a miniaturised, self-powered unit placed in the lower leg in a short, minimally invasive procedure under local anaesthesia.

The unit does not require patient activation, recharging or recurring visits to the doctor and works on the clinically proven mode of action of percutaneous tibial nerve stimulation.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

With the acquisition, Coloplast aims to initiate clinical studies of the device next year.

The company also expects to obtain pre-market approval for a Class III device in the US and EU market approvals in the 2024-2025 timeframe.

Coloplast president and CEO Kristian Villumsen said: “I am excited about the prospects of the Nine Continents device and pleased to confirm our commitment to the Interventional Urology business with this acquisition in the large OAB market.

“There is a large group of patients in the US and abroad, suffering from OAB, and with Nine Continents’ innovative, minimally invasive device, we hope to help these people live a better life.”

The acquisition is debt-financed, using existing credit facilities.

Piper Sandler is serving as financial advisor to Coloplast while Davis Polk & Wardwell LLP is serving as legal counsel for the company.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
SC MEDICA’s minimally invasive, radiation free spinal facet fixation system, FFX® is transforming spinal pain management and improving outcomes for surgeons and patients alike. Learn how SC MEDICA’s award-winning technology is redefining standards in facet joint pain treatment.

Discover the Impact